Bisphosphonate-associated osteonecrosis of the jaw 2 years after teeth extractions: a case report solved with non-invasive treatment

Eur Rev Med Pharmacol Sci. 2014;18(9):1391-7.

Abstract

Bisphosphonates are a type of drugs known to inhibit bone resorption through complex interventions. Their primary mechanism of action is aimed at the cellular level, inhibiting osteoclast activity and, thus, bone resorption. Bisphosphonates are, therefore, very widely used, with many patients receiving continuous treatment for years. But it is well known that these drugs can produce osteonecrosis of the jaw and this is their principal risk. A 75-year-old woman received dental treatment before starting intravenous BP therapy for a breast cancer. She started intravenous bisphosphonate treatment with monthly protocol and after two years the patient presented a wound compatible with osteonecrosis of the jaw.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Infective Agents, Local / therapeutic use
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / diagnosis
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / drug therapy
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / etiology*
  • Bone Density Conservation Agents / administration & dosage
  • Bone Density Conservation Agents / adverse effects*
  • Breast Neoplasms / drug therapy*
  • Diphosphonates / administration & dosage
  • Diphosphonates / adverse effects*
  • Drug Administration Schedule
  • Female
  • Humans
  • Imidazoles / administration & dosage
  • Imidazoles / adverse effects*
  • Infusions, Intravenous
  • Mouthwashes / therapeutic use
  • Radiography, Panoramic
  • Time Factors
  • Tooth Extraction*
  • Treatment Outcome
  • Zoledronic Acid

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents, Local
  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles
  • Mouthwashes
  • Zoledronic Acid